Literature DB >> 7277383

New antiarrhythmic agents. 6. Quantitative structure-activity relationships of aminoxylidides.

P A Tenthorey, A J Block, R A Ronfeld, P D McMaster, E W Byrnes.   

Abstract

The synthesis and pharmacological evaluation of primary and tertiary aminoxylidides with the amino group in the 2-7 position of the acyl chain are described. 2,6-Xylidine was acylated with haloacyl halides and converted to the target compounds by direct amination or by the Gabriel procedure. Alternatively, 2,6-xylidine was coupled with keto acids, and the ketoxylidides were converted to the amines by reductive amination. The target compounds were evaluated in mice both for antiarrhythmic efficacy against chloroform-induced tachycardia and for central nervous system toxicity. Experimentally determined values of partition coefficients and pKa values were used for quantitative structure-activity analyses. While the antiarrhythmic activity could be described as a function of log P alone, the CNS toxicity was best described as a function of both log P and pKa. The results suggest that antiarrhythmic potency can be increased by increasing lipophilicity, while the therapeutic index can be improved by increasing the pKa.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7277383     DOI: 10.1021/jm00139a007

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  3 in total

1.  Kinetics of local anesthetic inhibition of neuronal sodium currents. pH and hydrophobicity dependence.

Authors:  D M Chernoff; G R Strichartz
Journal:  Biophys J       Date:  1990-07       Impact factor: 4.033

2.  Tonic and phasic block of neuronal sodium currents by 5-hydroxyhexano-2',6'-xylide, a neutral lidocaine homologue.

Authors:  D M Chernoff; G R Strichartz
Journal:  J Gen Physiol       Date:  1989-06       Impact factor: 4.086

3.  The solution conformations of lidocaine analogues.

Authors:  P D McMaster; V J Noris; C E Stankard; E W Byrnes; P R Guzzo
Journal:  Pharm Res       Date:  1991-08       Impact factor: 4.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.